Clinical Cancer Research The Science of Cancer Health Disparities Stand Up to Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 14, 5825-5832, September 15, 2008. doi: 10.1158/1078-0432.CCR-07-5104
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Da Forno, P. D.
Right arrow Articles by Saldanha, G. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Da Forno, P. D.
Right arrow Articles by Saldanha, G. S.

Imaging, Diagnosis, Prognosis

WNT5A Expression Increases during Melanoma Progression and Correlates with Outcome

Philip D. Da Forno1, J. Howard Pringle1, Peter Hutchinson3, Joy Osborn3, Qiang Huang1, Linda Potter1, Rachael A. Hancox1, Alan Fletcher2 and Gerald S. Saldanha1

Authors' Affiliations: 1 Department of Cancer Studies and Molecular Medicine, University of Leicester; Departments of 2 Histopathology and 3 Dermatology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

Requests for reprints: Gerald Saldanha, Department of Cancer Studies and Molecular Medicine, University of Leicester, Level 3 RK-CSB, Leicester Royal Infirmary, Leicester LE2 7LX, United Kingdom. Phone: 44-116-252-3228; Fax: 44-116-254-1414; E-mail: gss4{at}le.ac.uk.

Purpose: Wnt ligands play a major role in development and are important in cancer. Expression microarray analysis correlates one member of this family, WNT5A, to a subclass of melanomas with increased motility and invasion. There are no large studies of clinical samples primarily addressing the importance of WNT5A in melanoma progression or outcome. Therefore, this study aimed to assess the protein expression of WNT5A during melanoma progression and its effect on outcome.

Experimental Design: Expression of WNT5A was determined in a series of 59 primary melanomas with matched metastases. To provide a benchmark of progression against which to assess WNT5A, expression of p16ink4a was analyzed, as this has been previously well documented in melanoma. The effect of WNT5A protein expression on outcome was assessed in 102 melanomas.

Results: Cytoplasmic WNT5A showed a trend of increasing expression with melanoma progression (P = 0.013), whereas there was diminishing p16ink4a expression (P = 0.006). Nevi showed relatively strong WNT5A expression. Strong cytoplasmic WNT5A was an independent risk factor for reduced metastasis-free and overall survival in multivariate analysis (P = 0.001 and 0.003, respectively).

Conclusion: Cytoplasmic WNT5A increases with melanoma progression and strong expression is associated with poor outcome.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.